tak-637 and Colonic-Diseases--Functional

tak-637 has been researched along with Colonic-Diseases--Functional* in 1 studies

Reviews

1 review(s) available for tak-637 and Colonic-Diseases--Functional

Article	Year
TAK-637. Takeda. Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:10 Abbott and Takeda are developing TAK-637, an orally active NK1 antagonist, for the potential treatment of urinary incontinence, depression, irritable bowel syndrome and pollakiuria. By November 1999, it was in phase II trials in Europe and phase I in Japan and the US for urinary incontinence [348496], [350686]. By October 2000, phase II trials had been initiated in the US for urinary incontinence, depression and IBS [381167], [386950], [419868], and in May 2001, these were scheduled to finish in 2002 [412024]. Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colonic Diseases, Functional; Depression; Humans; Naphthyridines; Neurokinin-1 Receptor Antagonists; Structure-Activity Relationship; Urinary Incontinence	2001

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:10

Abbott and Takeda are developing TAK-637, an orally active NK1 antagonist, for the potential treatment of urinary incontinence, depression, irritable bowel syndrome and pollakiuria. By November 1999, it was in phase II trials in Europe and phase I in Japan and the US for urinary incontinence [348496], [350686]. By October 2000, phase II trials had been initiated in the US for urinary incontinence, depression and IBS [381167], [386950], [419868], and in May 2001, these were scheduled to finish in 2002 [412024].

Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colonic Diseases, Functional; Depression; Humans; Naphthyridines; Neurokinin-1 Receptor Antagonists; Structure-Activity Relationship; Urinary Incontinence

2001